{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T02:44:46Z","timestamp":1761187486334,"version":"build-2065373602"},"reference-count":26,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCDD"],"abstract":"<jats:p>Background: Wild-type transthyretin cardiac amyloidosis (ATTRwt-CM) is a frequent but underdiagnosed cause of heart failure with preserved ejection fraction (HFpEF) and left ventricular hypertrophy (LVH). Early identification is essential given the availability of disease-modifying therapies. The T-Amylo and Davies scores are non-invasive tools for estimating ATTR CM probability, but their comparative performance in the same real-world population is not well defined. Objectives: To compare the diagnostic accuracy of T-Amylo and Davies scores in consecutive patients referred for suspected cardiac amyloidosis. Methods: We retrospectively analyzed 81 patients (mean age 76.8 \u00b1 8.3 years, 74% male) who underwent a standardized work-up: ECG, echocardiography with strain, NT-proBNP and troponin, bone scintigraphy, and immunofixation. ATTR CM was diagnosed according to established non-biopsy criteria. Both scores were calculated retrospectively, and sensitivity, specificity, predictive values, accuracy, and agreement were assessed. Results: ATTR CM was confirmed in 28 patients (34.5%). T-Amylo showed higher sensitivity (91.2% vs. 73.5%) and NPV (89.7% vs. 79.1%), while Davies had greater specificity (85.0% vs. 65.0%) and PPV (80.5% vs. 70.8%). Overall accuracy was comparable (T-Amylo 77.0% vs. Davies 79.7%). Agreement between scores was moderate (\u03ba = 0.59). Conclusions: T-Amylo is best suited as a screening tool for suspected ATTR CM, while Davies offers confirmatory value in high-probability cases. Combining these tools in a sequential strategy may optimize diagnostic efficiency, reduce unnecessary testing, and expedite initiation of disease-modifying therapy.<\/jats:p>","DOI":"10.3390\/jcdd12110417","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T02:03:48Z","timestamp":1761185028000},"page":"417","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Diagnostic Predictive Scores of Amyloid Cardiomyopathy in Patients with Heart Failure with Preserved Ejection Fraction and Left Ventricular Hypertrophy"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6568-6176","authenticated-orcid":false,"given":"Denise Cristiana","family":"Faro","sequence":"first","affiliation":[{"name":"Department of General Surgery and Medical-Surgical Specialties, University of Catania, Via S. Sofia 78, 95123 Catania, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrizia","family":"Romeo","sequence":"additional","affiliation":[{"name":"Department of General Surgery and Medical-Surgical Specialties, University of Catania, Via S. Sofia 78, 95123 Catania, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9328-4417","authenticated-orcid":false,"given":"Valentina","family":"Losi","sequence":"additional","affiliation":[{"name":"Department of General Surgery and Medical-Surgical Specialties, University of Catania, Via S. Sofia 78, 95123 Catania, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dario","family":"Simonetti","sequence":"additional","affiliation":[{"name":"Department of General Surgery and Medical-Surgical Specialties, University of Catania, Via S. Sofia 78, 95123 Catania, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5156-7723","authenticated-orcid":false,"given":"Davide","family":"Capodanno","sequence":"additional","affiliation":[{"name":"Department of General Surgery and Medical-Surgical Specialties, University of Catania, Via S. Sofia 78, 95123 Catania, Italy"},{"name":"Cardiology Unit\u2014CAST, AOU Policlinico \u201cG. Rodolico-S. Marco\u201d, Via S. Sofia 76, 95123 Catania, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7059-7525","authenticated-orcid":false,"given":"Ines Paola","family":"Monte","sequence":"additional","affiliation":[{"name":"Department of General Surgery and Medical-Surgical Specialties, University of Catania, Via S. Sofia 78, 95123 Catania, Italy"},{"name":"Cardiology Unit\u2014CAST, AOU Policlinico \u201cG. Rodolico-S. Marco\u201d, Via S. Sofia 76, 95123 Catania, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","article-title":"Diagnosis and treatment of cardiac amyloidosis: A position statement of the ESC Working Group on Myocardial and Pericardial Diseases","volume":"42","author":"Rapezzi","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","author":"Robles","year":"2015","journal-title":"Eur. Heart J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/ejhf.3186","article-title":"Prevalence of wild-type transthyretin amyloidosis in a prospective heart failure cohort with preserved and mildly reduced ejection fraction: Results of the Amylo-VIP-HF study","volume":"26","author":"Tubben","year":"2024","journal-title":"Eur. J. Heart Fail."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/ehf2.15112","article-title":"Prevalence of transthyretin cardiac amyloidosis in undifferentiated heart failure with preserved ejection fraction","volume":"12","author":"Healy","year":"2025","journal-title":"ESC Heart Fail."},{"key":"ref_5","first-page":"301","article-title":"Prevalence of transthyretin cardiac amyloidosis in patients with heart failure with preserved ejection fraction: The PRACTICA study","volume":"78","author":"Yun","year":"2025","journal-title":"Rev. Esp. Cardiol. (Engl. Ed.)"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1001\/jama.2024.0442","article-title":"Cardiac Amyloidosis Due to Transthyretin Protein: A Review","volume":"331","author":"Ruberg","year":"2024","journal-title":"JAMA"},{"key":"ref_7","first-page":"2025","article-title":"Evaluation of the 2021 ESC recommendations for family screening in hereditary transthyretin cardiac amyloidosis","volume":"26","author":"Muller","year":"2024","journal-title":"Eur. J. Heart Fail."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2022.11.022","article-title":"2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis","volume":"81","author":"Kittleson","year":"2023","journal-title":"JACC"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","article-title":"2023 ESC Guidelines for the management of cardiomyopathies: Developed by the task force on the management of cardiomyopathies of the European Society of Cardiology (ESC)","volume":"44","author":"Arbelo","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/j.jacc.2025.04.016","article-title":"The Evolving Therapeutic Paradigm for Cardiac Amyloidosis","volume":"85","author":"Kadakia","year":"2025","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ejim.2024.01.001","article-title":"Breakthrough advances enhancing care in ATTR amyloid cardiomyopathy","volume":"123","author":"Porcari","year":"2024","journal-title":"Eur. J. Intern. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1056\/NEJMoa2300757","article-title":"Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis","volume":"389","author":"Maurer","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2305434","article-title":"Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy","volume":"390","author":"Gillmore","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2409134","article-title":"Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy","volume":"392","author":"Fontana","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1056\/NEJMoa2412309","article-title":"CRISPR-Cas9 Gene Editing with Nexiguran Ziclumeran for ATTR Cardiomyopathy","volume":"391","author":"Fontana","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.jcmg.2023.05.002","article-title":"Development and Validation of a Prediction Model and Score for Transthyretin Cardiac Amyloidosis Diagnosis","volume":"16","author":"Jimenez","year":"2023","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1001\/jamacardio.2022.1781","article-title":"A Simple Score to Identify Increased Risk of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction","volume":"7","author":"Davies","year":"2022","journal-title":"JAMA Cardiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1093\/eurjpc\/zwaa027","article-title":"Diagnostic and prognostic value of low QRS voltages in cardiomyopathies: Old but gold","volume":"29","author":"Valentini","year":"2022","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.jacc.2008.12.014","article-title":"AHA\/ACCF\/HRS recommendations for the standardization and interpretation of the electrocardiogram: Part IV: The ST segment, T and U waves, and the QT interval: A scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society. Endorsed by the International Society for Computerized Electrocardiology","volume":"53","author":"Rautaharju","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"A31","DOI":"10.1016\/j.echo.2022.06.006","article-title":"Practical Points for Echocardiography in Cardiac Amyloidosis","volume":"35","author":"Cuddy","year":"2022","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"176","DOI":"10.36628\/ijhf.2025.0018","article-title":"T-Amylo Score for the Diagnosis of Transthyretin Cardiac Amyloidosis in Patients With Acute Heart Failure","volume":"7","author":"Burgos","year":"2025","journal-title":"Int. J. Heart Fail."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.cardfail.2024.11.016","article-title":"Performance of Clinical Scoring Systems in the Diagnosis of Transthyretin Amyloid Cardiomyopathy in a Diverse Patient Cohort","volume":"31","author":"Greenberg","year":"2025","journal-title":"J. Card. Fail."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1016\/j.mayocp.2021.04.023","article-title":"Artificial Intelligence-Enhanced Electrocardiogram for the Early Detection of Cardiac Amyloidosis","volume":"96","author":"Grogan","year":"2021","journal-title":"Mayo Clin. Proc."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Slivnick, J.A., Hawkes, W., Oliveira, J., Woodward, G., Akerman, A., Gomez, A., Hamza, I., Desai, V.K., Barrett-O\u2019kEefe, Z., and Grogan, M. (2025). Cardiac amyloidosis detection from a single echocardiographic video clip: A novel artificial intelligence-based screening tool. Eur. Heart J., advance online publication.","DOI":"10.1093\/eurheartj\/ehaf387"}],"container-title":["Journal of Cardiovascular Development and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2308-3425\/12\/11\/417\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T02:43:00Z","timestamp":1761187380000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2308-3425\/12\/11\/417"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,22]]},"references-count":26,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["jcdd12110417"],"URL":"https:\/\/doi.org\/10.3390\/jcdd12110417","relation":{},"ISSN":["2308-3425"],"issn-type":[{"value":"2308-3425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,22]]}}}